TISIDB

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00017 SH2 domain PF00018 SH3 domain PF07653 Variant SH3 domain
Function	May mediate the transduction of intracellular signals.

> Gene Ontology [ TOP ]
Biological Process	GO:0000186 activation of MAPKK activity GO:0003002 regionalization GO:0007254 JNK cascade GO:0007265 Ras protein signal transduction GO:0007389 pattern specification process GO:0007507 heart development GO:0009952 anterior/posterior pattern specification GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0022604 regulation of cell morphogenesis GO:0031098 stress-activated protein kinase signaling cascade GO:0031589 cell-substrate adhesion GO:0032147 activation of protein kinase activity GO:0033674 positive regulation of kinase activity GO:0034446 substrate adhesion-dependent cell spreading GO:0035270 endocrine system development GO:0043405 regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0045785 positive regulation of cell adhesion GO:0045860 positive regulation of protein kinase activity GO:0048538 thymus development GO:0048732 gland development GO:0051403 stress-activated MAPK cascade GO:0060017 parathyroid gland development GO:0071900 regulation of protein serine/threonine kinase activity GO:1900024 regulation of substrate adhesion-dependent cell spreading GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
Molecular Function	GO:0005070 SH3/SH2 adaptor activity GO:0030674 protein binding, bridging GO:0035591 signaling adaptor activity GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0060090 binding, bridging GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005913 cell-cell adherens junction

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04010 MAPK signaling pathway hsa04012 ErbB signaling pathway hsa04015 Rap1 signaling pathway hsa04062 Chemokine signaling pathway hsa04510 Focal adhesion hsa04666 Fc gamma R-mediated phagocytosis hsa04722 Neurotrophin signaling pathway hsa04810 Regulation of actin cytoskeleton hsa04910 Insulin signaling pathway
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-186763: Downstream signal transduction R-HSA-170968: Frs2-mediated activation R-HSA-168256: Immune System R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-8875555: MET activates RAP1 and RAC1 R-HSA-8875878: MET promotes cell motility R-HSA-8875656: MET receptor recycling R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-169893: Prolonged ERK activation events R-HSA-912631: Regulation of signaling by CBL R-HSA-162582: Signal Transduction R-HSA-449147: Signaling by Interleukins R-HSA-6806834: Signaling by MET R-HSA-186797: Signaling by PDGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04015 Rap1 signaling pathway
hsa04062 Chemokine signaling pathway
hsa04510 Focal adhesion
hsa04666 Fc gamma R-mediated phagocytosis
hsa04722 Neurotrophin signaling pathway
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway

Reactome

R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-186763: Downstream signal transduction
R-HSA-170968: Frs2-mediated activation
R-HSA-168256: Immune System
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-8875555: MET activates RAP1 and RAC1
R-HSA-8875878: MET promotes cell motility
R-HSA-8875656: MET receptor recycling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-169893: Prolonged ERK activation events
R-HSA-912631: Regulation of signaling by CBL
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-6806834: Signaling by MET
R-HSA-186797: Signaling by PDGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CRKL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CRKL in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -3.06; FDR: 0.01020	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 1.08	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CRKL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.096	0.646
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.103	0.959
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.24	0.867
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.105	0.728
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.179	0.925
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.013	0.996
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.273	0.514
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.269	0.887
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.322	0.875
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.246	0.842
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.553	0.768
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.116	0.119

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CRKL in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRKL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRKL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRKL. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRKL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CRKL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CRKL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CRKL
Name	v-crk avian sarcoma virus CT10 oncogene homolog-like
Aliases	Crk-like protein
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CRKL collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CRKL